Prescribing patterns amongst UK dermatologists for the treatment of alopecia areata, female pattern hair loss, and frontal fibrosing alopecia

John Frewen, Dalia Alsaadi, Leila Asfour, Sharon Belmo, Alyson Bryden, Caroline Champagne, Nicola Clayton, Nicola Cooke, Donna M. Cummins, David Fairhurst, Paul Farrant, Gordan Hale, Susan Holmes, Thomas Harries, Ruth Jones, Sanja Karanovic, Manjit R. Kaur, Nekma Meah, Megan Mowbray, Archana Rao, Nasim Rouhani, Nicola Salmon, Anita Takwale, Martin Wade, Sharon Wong, Shirin Zaheri, Yusur Al-Nuaimi, Matthew Harries
{"title":"Prescribing patterns amongst UK dermatologists for the treatment of alopecia areata, female pattern hair loss, and frontal fibrosing alopecia","authors":"John Frewen,&nbsp;Dalia Alsaadi,&nbsp;Leila Asfour,&nbsp;Sharon Belmo,&nbsp;Alyson Bryden,&nbsp;Caroline Champagne,&nbsp;Nicola Clayton,&nbsp;Nicola Cooke,&nbsp;Donna M. Cummins,&nbsp;David Fairhurst,&nbsp;Paul Farrant,&nbsp;Gordan Hale,&nbsp;Susan Holmes,&nbsp;Thomas Harries,&nbsp;Ruth Jones,&nbsp;Sanja Karanovic,&nbsp;Manjit R. Kaur,&nbsp;Nekma Meah,&nbsp;Megan Mowbray,&nbsp;Archana Rao,&nbsp;Nasim Rouhani,&nbsp;Nicola Salmon,&nbsp;Anita Takwale,&nbsp;Martin Wade,&nbsp;Sharon Wong,&nbsp;Shirin Zaheri,&nbsp;Yusur Al-Nuaimi,&nbsp;Matthew Harries","doi":"10.1002/jvc2.495","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Therapeutic management of hair loss is frequently complicated by a lack of high-quality evidence and reliant on the use of unlicensed therapies. Treatment decision-making is predominantly based on expert opinion, local availability, personal experience, and cost, which make informed choices challenging for clinicians and patients in this area.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>The aims were to determine prescribing patterns amongst UK Dermatologists with a special interest in hair disorders, when treating mild-moderate alopecia areata (AA), severe AA (including alopecia totalis/alopecia universalis), female pattern hair loss (FPHL) and frontal fibrosing alopecia (FFA).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Consultant members of the British Hair and Nail society, a special interest group affiliated to the British Association of Dermatologists, were invited to participate from across the United Kingdom. Participants were questioned on their current prescribing patterns in both NHS and private practice, were asked to rank their first-to-fifth line treatments for each condition and highlight the treatment they perceive as most effective for each disorder.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Twenty-six Consultant Dermatologists completed the questionnaire, from twenty-three institutions. For treatment of mild-moderate AA, topical corticosteroids were used first line amongst 65% (<i>n</i> = 17) of respondents, and 82% (<i>n</i> = 23) reported that intralesional corticosteroids were the most effective treatment. For severe AA, oral corticosteroids were used first line amongst 38% (<i>n</i> = 10) of respondents, and 25% (<i>n</i> = 8) reported that oral corticosteroids were the most effective treatment. For FPHL, topical minoxidil was used first line amongst 84% (<i>n</i> = 25) of respondents, and 42% (<i>n</i> = 10) reported that oral minoxidil was the most effective treatment. For FFA, topical corticosteroids were used first line amongst 62% (<i>n</i> = 16) of respondents, and 37% (<i>n</i> = 14) reported that hydroxychloroquine was the most effective treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study reports real-world prescribing practices amongst dermatologists treating common hair loss conditions. These results aim to support clinicians with decision making for managing hair loss conditions.</p>\n </section>\n </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 1","pages":"72-81"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.495","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JEADV clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jvc2.495","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Therapeutic management of hair loss is frequently complicated by a lack of high-quality evidence and reliant on the use of unlicensed therapies. Treatment decision-making is predominantly based on expert opinion, local availability, personal experience, and cost, which make informed choices challenging for clinicians and patients in this area.

Objectives

The aims were to determine prescribing patterns amongst UK Dermatologists with a special interest in hair disorders, when treating mild-moderate alopecia areata (AA), severe AA (including alopecia totalis/alopecia universalis), female pattern hair loss (FPHL) and frontal fibrosing alopecia (FFA).

Methods

Consultant members of the British Hair and Nail society, a special interest group affiliated to the British Association of Dermatologists, were invited to participate from across the United Kingdom. Participants were questioned on their current prescribing patterns in both NHS and private practice, were asked to rank their first-to-fifth line treatments for each condition and highlight the treatment they perceive as most effective for each disorder.

Results

Twenty-six Consultant Dermatologists completed the questionnaire, from twenty-three institutions. For treatment of mild-moderate AA, topical corticosteroids were used first line amongst 65% (n = 17) of respondents, and 82% (n = 23) reported that intralesional corticosteroids were the most effective treatment. For severe AA, oral corticosteroids were used first line amongst 38% (n = 10) of respondents, and 25% (n = 8) reported that oral corticosteroids were the most effective treatment. For FPHL, topical minoxidil was used first line amongst 84% (n = 25) of respondents, and 42% (n = 10) reported that oral minoxidil was the most effective treatment. For FFA, topical corticosteroids were used first line amongst 62% (n = 16) of respondents, and 37% (n = 14) reported that hydroxychloroquine was the most effective treatment.

Conclusions

This study reports real-world prescribing practices amongst dermatologists treating common hair loss conditions. These results aim to support clinicians with decision making for managing hair loss conditions.

Abstract Image

处方模式之间的英国皮肤科医生治疗斑秃,女性型脱发,额纤维化脱发
背景:脱发的治疗管理往往因缺乏高质量的证据和依赖于使用未经许可的疗法而变得复杂。治疗决策主要基于专家意见、当地可用性、个人经验和成本,这使得临床医生和患者在这一领域做出明智的选择具有挑战性。目的是确定英国皮肤科医生在治疗轻中度斑秃(AA)、重度斑秃(包括完全性脱发/完全性脱发)、女性型脱发(FPHL)和额部纤维化性脱发(FFA)时对头发疾病的特殊兴趣的处方模式。方法英国头发和指甲协会(一个隶属于英国皮肤科医师协会的特殊兴趣小组)的顾问成员被邀请参加来自英国各地的研究。参与者被问及他们目前在NHS和私人诊所的处方模式,被要求对每种疾病的第一到第五行治疗进行排名,并强调他们认为对每种疾病最有效的治疗。结果来自23家机构的26名皮肤科会诊医师完成问卷调查。对于轻中度AA的治疗,65% (n = 17)的应答者使用局部皮质类固醇作为一线治疗,82% (n = 23)的应答者报告病灶内皮质类固醇是最有效的治疗方法。对于严重AA, 38% (n = 10)的应答者将口服皮质激素作为一线治疗,25% (n = 8)的应答者报告口服皮质激素是最有效的治疗方法。对于FPHL, 84% (n = 25)的应答者首选外用米诺地尔,42% (n = 10)的应答者报告口服米诺地尔是最有效的治疗方法。对于FFA, 62% (n = 16)的应答者首选外用皮质类固醇,37% (n = 14)的应答者报告羟氯喹是最有效的治疗方法。结论:本研究报告了皮肤科医生治疗常见脱发情况的真实世界处方做法。这些结果旨在支持临床医生对脱发状况的管理决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信